Signifor La 20, 40, 60 mg Powder for suspension for injection
PDF Leaflet Revision Date: 11 September 2025
Clinical Summary
Quick overview from the medicine insert
Indication
Treatment of acromegaly as second-line therapy.
Dosage (summary)
Initial dose: 40 mg IM every 4 weeks; may increase to 60 mg if needed.
Special Populations
- Elderly patients
- Renal impairment
- Hepatic impairment
Pregnancy & Breastfeeding
Not recommended during pregnancy or breastfeeding; potential reproductive toxicity.
Key Drug Interactions
- Ciclosporin
- QT prolonging medications
- Bradycardic medications
Contraindications
- Hypersensitivity to pasireotide
- Severe hepatic impairment (Child Pugh C)
Common side effects
- Hyperglycaemia
- Diarrhoea
- Cholelithiasis
- Fatigue
Counselling Points
- Monitor blood glucose regularly.
- Report signs of liver dysfunction.
- Use contraception if of childbearing potential.
Serious warnings
- Risk of hyperglycaemia and ketoacidosis
- QT prolongation
- Hypocortisolism
Important Disclaimer
The Signifor La 20, 40, 60 mg Powder for suspension for injection professional information leaflet below is the property of Key Oncologics D and is provided on Medinsert exactly as issued, with no.. alterations or editorial changes. We make every effort to keep content current by updating documents as soon as new versions become available. Medinsert serves as a trusted access point for healthcare professionals, but does not replace official sources or clinical judgement. For more details, please read our full disclaimer. read more>>
Healthcare Professionals Only
This content is for registered healthcare professionals
Sign in or create a free account to read the full package insert.
Free for HPCSA-registered professionals. Powered by Medinsert.
